Do analysts rate ADTX or TRVN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trevena 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, ADTX or TRVN?

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.19 -$41.71M -$100.79 thousand N/A Trevena $443K 0.02 -$40.29M -$47.04 N/A

Is ADTX or TRVN more profitable?

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Trevena N/A N/A -119.55%

Is CMRA or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Trevena N/A N/A -119.55%

Is EFTR or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A Trevena N/A N/A -119.55%

Is TRVN or SYRS more profitable?

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is EVLO or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Trevena N/A N/A -119.55%

Trevena (TRVN) Competitors

$0.01 0.00 (0.00%)

As of 07/20/2026 10:11 AM Eastern

Compare

TRVN vs. ADTX, CMRA, EFTR, SYRS, and EVLO

Should you buy Trevena stock or one of its competitors? MarketBeat compares Trevena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevena include Aditxt (ADTX), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Syros Pharmaceuticals (SYRS), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does Trevena compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Trevena	Neutral

Aditxt has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Trevena has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Trevena	N/A	N/A	-119.55%

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.19	-$41.71M	-$100.79 thousand	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trevena	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Aditxt and Trevena tied by winning 6 of the 12 factors compared between the two stocks.

How does Trevena compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Comera Life Sciences has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

13.6% of Trevena shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Trevena compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Company	Net Margins	Return on Equity	Return on Assets
eFFECTOR Therapeutics	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

eFFECTOR Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

eFFECTOR Therapeutics has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eFFECTOR Therapeutics	N/A	N/A	-$35.81M	-$13.08	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
eFFECTOR Therapeutics	Neutral
Trevena	Neutral

Summary

eFFECTOR Therapeutics beats Trevena on 7 of the 8 factors compared between the two stocks.

How does Trevena compare to Syros Pharmaceuticals?

Trevena (NASDAQ:TRVN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

13.6% of Trevena shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

In the previous week, Syros Pharmaceuticals had 2 more articles in the media than Trevena. MarketBeat recorded 2 mentions for Syros Pharmaceuticals and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Syros Pharmaceuticals	Neutral

Trevena has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Summary

Syros Pharmaceuticals beats Trevena on 7 of the 11 factors compared between the two stocks.

How does Trevena compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Evelo Biosciences has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Trevena has higher revenue and earnings than Evelo Biosciences. Trevena is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Trevena	Neutral

Summary

Evelo Biosciences and Trevena tied by winning 4 of the 8 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVN vs. The Competition

Export

Metric	Trevena	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11K	$968.20M	$6.80B	$12.40B
Dividend Yield	N/A	4.84%	2.67%	9.39%
P/E Ratio	0.00	1.51	27.08	24.12
Price / Sales	0.02	112.99	516.47	92.58
Price / Cash	N/A	22.05	26.68	47.25
Price / Book	0.00	8.68	10.63	6.23
Net Income	-$40.29M	-$2.87M	$3.60B	$331.53M
7 Day Performance	N/A	-1.16%	-1.08%	-1.30%
1 Month Performance	N/A	1.85%	1.28%	-1.40%
1 Year Performance	N/A	29.30%	24.71%	18.15%

Trevena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVN Trevena	N/A	$0.01 flat	N/A	-98.8%	$11K	$443K	N/A	40
ADTX Aditxt	0.585 of 5 stars	$0.00 -11.4%	N/A	-100.0%	$3K	$14.34K	N/A	60	Gap Down
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
EFTR eFFECTOR Therapeutics	N/A	$0.00 flat	N/A	N/A	$3K	N/A	N/A	10
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-98.0%	$3K	$386K	N/A	120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevena (TRVN) Competitors

TRVN vs. ADTX, CMRA, EFTR, SYRS, and EVLO

How does Trevena compare to Aditxt?

Summary

How does Trevena compare to Comera Life Sciences?

Summary

How does Trevena compare to eFFECTOR Therapeutics?

Summary

How does Trevena compare to Syros Pharmaceuticals?

Summary

How does Trevena compare to Evelo Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevena (TRVN) Competitors

TRVN vs. ADTX, CMRA, EFTR, SYRS, and EVLO

How does Trevena compare to Aditxt?

Does the media favor ADTX or TRVN?

Which has more risk and volatility, ADTX or TRVN?

Do insiders & institutionals have more ownership in ADTX or TRVN?

Is ADTX or TRVN more profitable?

Which has preferable earnings & valuation, ADTX or TRVN?

Do analysts rate ADTX or TRVN?

Summary

How does Trevena compare to Comera Life Sciences?

Which has more volatility & risk, CMRA or TRVN?

Does the media prefer CMRA or TRVN?

Is CMRA or TRVN more profitable?

Do insiders & institutionals hold more shares of CMRA or TRVN?

Which has better earnings and valuation, CMRA or TRVN?

Summary

How does Trevena compare to eFFECTOR Therapeutics?

Is EFTR or TRVN more profitable?

Which has more risk and volatility, EFTR or TRVN?

Do insiders and institutionals hold more shares of EFTR or TRVN?

Which has higher valuation and earnings, EFTR or TRVN?

Does the media prefer EFTR or TRVN?

Summary

How does Trevena compare to Syros Pharmaceuticals?

Is TRVN or SYRS more profitable?

Do insiders & institutionals believe in TRVN or SYRS?

Which has better earnings and valuation, TRVN or SYRS?

Does the media favor TRVN or SYRS?

Which has more volatility and risk, TRVN or SYRS?

Summary

How does Trevena compare to Evelo Biosciences?

Which has more volatility and risk, EVLO or TRVN?

Which has stronger valuation and earnings, EVLO or TRVN?

Is EVLO or TRVN more profitable?

Do institutionals and insiders hold more shares of EVLO or TRVN?

Does the media refer more to EVLO or TRVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools